AstraZeneca's Innovative Cancer Study: A Potential Game-Changer?
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AstraZeneca's ongoing study, titled 'A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (CERTIS1)', aims to evaluate the safety and effectiveness of AZD9574, alone and with other anti-cancer drugs, in patients with advanced cancers.
The study tests AZD9574, an experimental drug, both as a standalone treatment and in combination with other drugs like Temozolomide, Trastuzumab Deruxtecan, and Datopotamab Deruxtecan. These interventions target various advanced solid tumors, including breast, ovarian, pancreatic, and prostate cancers.
This interventional study is non-randomized and follows a sequential intervention model. It is open-label, meaning no masking is involved, and its primary purpose is treatment-focused. The study is designed to escalate doses to determine safety and efficacy.
Key dates for the study include its start on June 24, 2022, with the latest update submitted on July 23, 2025. These dates are crucial for tracking the study's progress and ensuring timely updates for stakeholders.
The study's progress could influence AstraZeneca's stock performance and investor sentiment, especially if the results show promising efficacy. As the study involves novel cancer treatments, it could impact the competitive landscape in oncology, potentially affecting other companies in the sector.
The study is currently recruiting, with further details available on the ClinicalTrials portal.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBC
3 hours ago
- CBC
Canadian delegation heads to Mexico to build trade opportunities
With trade negotiations with the U.S. seemingly at a standstill, a delegation of Canadian ministers has headed to Mexico to establish a more direct trade relationship.
Globe and Mail
4 hours ago
- Globe and Mail
Small Cell Lung Cancer Pipeline Outlook Report 2025: Key 100+ Companies and Breakthrough Therapies Shaping the Future Landscape
DelveInsight's, 'Small Cell Lung Cancer Pipeline Insight 2025' report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Small Cell Lung Cancer pipeline landscape. It covers the Small Cell Lung Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Small Cell Lung Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive Small Cell Lung Cancer Pipeline Report to explore emerging therapies, key Companies, and future treatment landscapes @ Small Cell Lung Cancer Pipeline Outlook Report Key Takeaways from the Small Cell Lung Cancer Pipeline Report In August 2025, AstraZeneca announced a Phase III study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with LS-SCLC Who Have Not Progressed Following Concurrent Chemoradiation Therapy. In August 2025, Amgen conducted a study is to compare the efficacy of tarlatamab with placebo as assessed by progression free survival (PFS). In August 2025, AbbVie organized a study is to assess adverse events and change in disease activity when Telisotuzumab Adizutecan (ABBV-400) is given in combination with a programmed cell death receptor 1 (PD1) inhibitor (budigalimab) to adult participants to treat NSCLC. DelveInsight's Small Cell Lung Cancer pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for Small Cell Lung Cancer treatment. The leading Small Cell Lung Cancer Companies such as Ascentage Pharma, Merck & Co, AstraZeneca, Advenchen Laboratories, GlaxoSmithKline, Advanced Accelerator Applications, Trillium Therapeutics, Vernalis, Oncoceutics, NewBio Therapeutics, Wigen Biomedicine, Linton Pharm, Carrick Therapeutics, Xencor, Jiangsu HengRui Medicine, Aileron Therapeutics, Roche, Ipsen, Celgene, Lee's Pharmaceutical Limited, AbbVie, G1 Therapeutics, Chipscreen Biosciences, Luye Pharma Group, Shanghai Henlius Biotech, CSPC ZhongQi Pharmaceutical Technology, Impact Therapeutics and others. Promising Small Cell Lung Cancer Pipeline Therapies such as Pembrolizumab (neoadjuvant), Cisplatin, Gemcitabine, AL8326, Durvalumab, Lurbinectedin, Pembrolizumab, Etoposide and others. Discover how the Small Cell Lung Cancer treatment paradigm is evolving. Access DelveInsight's in-depth Pipeline Analysis for a closer look at promising breakthroughs @ Small Cell Lung Cancer Clinical Trials and Studies Small Cell Lung Cancer Emerging Drugs Profile AMG 757: Amgen AMG 757 is a half-life extended (HLE) anti- delta-like ligand 3 (DLL3) x anti-CD3 BiTE (bispecific T cell engager) molecule. It is being investigated in Phase I clinical studies for the treatment of prostate cancer and Small cell lung cancer. APG-1252 is a highly potent, small-molecule based Bcl-2 family protein inhibitor drug. APG-1252 is designed to treat SCLC, NSCLC, lymphoma, and other solid tumors by selectively blocking Bcl-2 and Bcl-xL to restore the apoptosis process. The drug is in Phase I/II clinical studies for the treatment of SCLC. The Small Cell Lung Cancer Pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Small Cell Lung Cancer with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Small Cell Lung Cancer Treatment. Small Cell Lung Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Small Cell Lung Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Small Cell Lung Cancer market. Get a detailed analysis of the latest innovations in the Small Cell Lung Cancer Pipeline. Explore DelveInsight's expert-driven report today! @ Small Cell Lung Cancer Unmet Needs Small Cell Lung Cancer Companies Ascentage Pharma, Merck & Co, AstraZeneca, Advenchen Laboratories, GlaxoSmithKline, Advanced Accelerator Applications, Trillium Therapeutics, Vernalis, Oncoceutics, NewBio Therapeutics, Wigen Biomedicine, Linton Pharm, Carrick Therapeutics, Xencor, Jiangsu HengRui Medicine, Aileron Therapeutics, Roche, Ipsen, Celgene, Lee's Pharmaceutical Limited, AbbVie, G1 Therapeutics, Chipscreen Biosciences, Luye Pharma Group, Shanghai Henlius Biotech, CSPC ZhongQi Pharmaceutical Technology, Impact Therapeutics and others. Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Parenteral Intravitreal Subretinal Topical Molecule Type Small Cell Lung Cancer Products have been categorized under various Molecule types such as Monoclonal Antibody Peptides Polymer Small molecule Gene therapy Product Type Download DelveInsight's latest report to gain strategic insights into upcoming therapies and key Small Cell Lung Cancer Developments @ Small Cell Lung Cancer Market Drivers and Barriers, and Future Perspectives Scope of the Small Cell Lung Cancer Pipeline Report Coverage- Global Small Cell Lung Cancer Companies- Ascentage Pharma, Merck & Co, AstraZeneca, Advenchen Laboratories, GlaxoSmithKline, Advanced Accelerator Applications, Trillium Therapeutics, Vernalis, Oncoceutics, NewBio Therapeutics, Wigen Biomedicine, Linton Pharm, Carrick Therapeutics, Xencor, Jiangsu HengRui Medicine, Aileron Therapeutics, Roche, Ipsen, Celgene, Lee's Pharmaceutical Limited, AbbVie, G1 Therapeutics, Chipscreen Biosciences, Luye Pharma Group, Shanghai Henlius Biotech, CSPC ZhongQi Pharmaceutical Technology, Impact Therapeutics and others. Small Cell Lung Cancer Pipeline Therapies- Pembrolizumab (neoadjuvant), Cisplatin, Gemcitabine, AL8326, Durvalumab, Lurbinectedin, Pembrolizumab, Etoposide and others. Small Cell Lung Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Small Cell Lung Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Which companies are leading the race in Small Cell Lung Cancer drug development? Find out in DelveInsight's exclusive Pipeline Report—access it now! @ Small Cell Lung Cancer Emerging Drugs and Major Companies Table of Content Introduction Executive Summary Small Cell Lung Cancer: Overview Pipeline Therapeutics Therapeutic Assessment Small Cell Lung Cancer – DelveInsight's Analytical Perspective In-depth Commercial Assessment Small Cell Lung Cancer Collaboration Deals Late Stage Products (Phase III) Pembrolizumab: Merck & Co Mid Stage Products (Phase II) Dostarlimab: GlaxoSmithKline Early Stage Products (Phase I) AMG 757: Amgen Preclinical/Discovery Stage Products S 055746: Vernalis Inactive Products Small Cell Lung Cancer Key Companies Small Cell Lung Cancer Key Products Small Cell Lung Cancer- Unmet Needs Small Cell Lung Cancer- Market Drivers and Barriers Small Cell Lung Cancer- Future Perspectives and Conclusion Small Cell Lung Cancer Analyst Views Small Cell Lung Cancer Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
CTV News
4 hours ago
- CTV News
Champagne, Anand to meet with Mexican president to strengthen trade ties
Watch As Canada-U.S. trade talks are up in the air, Canada's federal government remains diligent to strengthen the country's trade ties. CTV's Colton Praill reports.
